These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26767080)

  • 41. Correction to: Safety and Effectiveness of Ipragliflozin in Elderly Versus Non-elderly Japanese Patients with Type 2 Diabetes: Subgroup Analysis of STELLA-LONG TERM.
    Nakamura I; Maegawa H; Tobe K; Uno S
    Diabetes Ther; 2021 Oct; 12(10):2801-2805. PubMed ID: 34463953
    [No Abstract]   [Full Text] [Related]  

  • 42. Correction to: Safety and Effectiveness of Ipragliflozin in Elderly Versus Non-elderly Japanese Patients with Type 2 Diabetes: Subgroup Analysis of STELLA-LONG TERM.
    Nakamura I; Maegawa H; Tobe K; Uno S
    Diabetes Ther; 2021 Jun; 12(6):1765-1768. PubMed ID: 34018149
    [No Abstract]   [Full Text] [Related]  

  • 43. Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): Interim results of a post-marketing surveillance study.
    Terauchi Y; Yokote K; Nakamura I; Sugamori H
    Expert Opin Pharmacother; 2016; 17(4):463-71. PubMed ID: 26800061
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.
    Iizuka T; Iemitsu K; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Kawata T; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyagi S; Hoshino K; Ishikawa M; Matsuzawa Y; Obana M; Sasai N; Kaneshige H; Minagawa F; Saito T; Shinoda K; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2016 Mar; 8(3):267. PubMed ID: 26858805
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study.
    Iemitsu K; Iizuka T; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Kawata T; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyagi S; Hoshino K; Ishikawa M; Obana M; Sasai N; Kaneshige H; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2016 May; 8(5):373-8. PubMed ID: 27081422
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.
    Ohki T; Isogawa A; Toda N; Tagawa K
    Clin Drug Investig; 2016 Apr; 36(4):313-9. PubMed ID: 26914659
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
    Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
    PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative effectiveness of sodium-glucose co-transporter 2 inhibitors for controlling hyperglycaemia in patients with type 2 diabetes: protocol for a systematic review and network meta-analysis.
    Chen M; Xie CG; Gao H; Zheng H; Chen Q; Fang JQ
    BMJ Open; 2016 Jan; 6(1):e010252. PubMed ID: 26826156
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy.
    Yamamoto C; Miyoshi H; Ono K; Sugawara H; Kameda R; Ichiyama M; Yamamoto K; Nomoto H; Nakamura A; Atsumi T
    Endocr J; 2016 Jun; 63(6):589-96. PubMed ID: 27052123
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials.
    Sakai S; Kaku K; Seino Y; Inagaki N; Haneda M; Sasaki T; Fukatsu A; Kakiuchi H; Samukawa Y
    Clin Ther; 2016 Apr; 38(4):843-862.e9. PubMed ID: 27021608
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.
    Kashiwagi A; Yoshida S; Nakamura I; Kazuta K; Ueyama E; Takahashi H; Satomi H; Kosakai Y; Kawamuki K
    J Diabetes Investig; 2016 Jul; 7(4):544-54. PubMed ID: 27181576
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ipragliflozin as an Initial Therapy in Drug Naïve Subjects with Type 2 Diabetes.
    Kutoh E; Wada A; Murayama T; Hirate M
    Drug Res (Stuttg); 2016 Jul; 66(7):345-50. PubMed ID: 27056638
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension.
    Tikkanen I; Chilton R; Johansen OE
    Curr Opin Nephrol Hypertens; 2016 Mar; 25(2):81-6. PubMed ID: 26808705
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial.
    Mita T; Katakami N; Shiraiwa T; Yoshii H; Onuma T; Kuribayashi N; Osonoi T; Kaneto H; Kosugi K; Umayahara Y; Yamamoto T; Matsumoto K; Yokoyama H; Tsugawa M; Gosho M; Shimomura I; Watada H;
    Diabetes Care; 2016 Mar; 39(3):455-64. PubMed ID: 26822324
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Caffeine intake enhances the benefits of sodium glucose transporter 2 inhibitor.
    Hashimoto Y; Tanaka M; Yamazaki M; Nakano K; Ushigome E; Okada H; Oda Y; Nakamura N; Fukui M
    Diabetes Metab Res Rev; 2016 Oct; 32(7):694-699. PubMed ID: 26891133
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and Safety of Alogliptin in Patients With Type 2 Diabetes: Analysis of the ATTAK-J Study.
    Takeda H; Sasai N; Ito S; Obana M; Takuma T; Takai M; Kaneshige H; Machimura H; Kanamori A; Nakajima K; Matsuba I
    J Clin Med Res; 2016 Feb; 8(2):130-40. PubMed ID: 26767082
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ACP Journal Club. In patients with type 2 diabetes and CV disease, empagliflozin reduced a composite of CV events at 3.1 years.
    Shekelle P
    Ann Intern Med; 2016 Jan; 164(2):JC2. PubMed ID: 26784492
    [No Abstract]   [Full Text] [Related]  

  • 58. Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes.
    Rosenstock J; Chuck L; González-Ortiz M; Merton K; Craig J; Capuano G; Qiu R
    Diabetes Care; 2016 Mar; 39(3):353-62. PubMed ID: 26786577
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
    Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
    J Pharmacol Sci; 2016 Mar; 130(3):159-69. PubMed ID: 26970780
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin.
    Kern M; Klöting N; Mark M; Mayoux E; Klein T; Blüher M
    Metabolism; 2016 Feb; 65(2):114-23. PubMed ID: 26773934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.